One man with advanced kidney cancer stayed stable for about 6 years
Original title: Long-term survival with immune checkpoint inhibitors combined with bevacizumab in advanced clear cell renal cell carcinoma: A case report.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is just one patient's story, so more studies in people are needed.
The short version
Doctors share the story of one man whose spreading kidney cancer was held in check by two drugs used together.
What was studied. This is a report about one patient, a 49-year-old man. He had stage IV clear cell kidney cancer that spread to his lungs, his adrenal gland, and his brain.
What they found. His cancer kept growing after surgery and several earlier drug treatments. He then got 4 cycles of camrelizumab with bevacizumab: A drug that acts on the blood vessels a tumor builds. In brain tumors it is used mainly for two things. One is to control symptoms from swelling. The other is to cut down how much steroid someone needs. See the glossary, and later tislelizumab with bevacizumab. His cancer became stable, and he has lived about 6 years so far. Doctors said he handled the treatment well.
What this means, and what it doesn't
What it could mean: For some people whose kidney cancer has spread, pairing an immune drug with bevacizumab: A drug that acts on the blood vessels a tumor builds. In brain tumors it is used mainly for two things. One is to control symptoms from swelling. The other is to cut down how much steroid someone needs. See the glossary may help hold the cancer still. The man in this report had not had an immune drug before. A doctor can say whether this kind of mix fits your case.
What it doesn't mean: This is one person's story, not a study. It does not show the treatment works for other people. The cancer did not go away. It only stopped growing for a time. This is not a cure and not a promise. The authors say more studies in people are still needed. Note too that this cancer started in the kidney, not in the brain.
Source: PubMed, October 9, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.